Literature DB >> 10683005

Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment.

C Henzen1, A Suter, E Lerch, R Urbinelli, X H Schorno, V A Briner.   

Abstract

BACKGROUND: Suppression of the adrenal response is an unpredictable consequence of glucocorticoid treatment. To investigate the kinetics of the adrenal response after short-term, high-dose glucocorticoid treatment, we measured the adrenal response to the low-dose (1 microg) corticotropin stimulation test.
METHODS: We studied 75 patients who received the equivalent of at least 25 mg prednisone daily for between 5 days and 30 days. After discontinuation of glucocorticoid treatment, 1 microg corticotropin was administered intravenously, and stimulated plasma cortisol concentrations were measured 30 min later. In patients with a suppressed response to 1 microg corticotropin, the test was repeated until stimulated plasma cortisol concentrations reached the normal range.
FINDINGS: The adrenal response to 1 microg corticotropin was suppressed in 34 patients and normal in 41. Subsequent low-dose corticotropin tests showed a steady recovery of the adrenal response within 14 days. In two patients, the adrenal response remained suppressed for several months. There was no correlation between plasma cortisol concentrations and the duration or dose of glucocorticoid treatment.
INTERPRETATION: Suppression of the adrenal response is common after short-term, high-dose glucocorticoid treatment. The low-dose corticotropin test is a sensitive and simple test to assess the adrenal response after such treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683005     DOI: 10.1016/S0140-6736(99)06290-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  51 in total

Review 1.  Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.

Authors:  G Umberto Meduri; Lisa Bridges; Mei-Chiung Shih; Paul E Marik; Reed A C Siemieniuk; Mehmet Kocak
Journal:  Intensive Care Med       Date:  2015-10-27       Impact factor: 17.440

2.  A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma.

Authors:  S Aburuz; L G Heaney; J Millership; J Gamble; J McElnay
Journal:  Br J Clin Pharmacol       Date:  2007-01       Impact factor: 4.335

Review 3.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Patients treated with immunosuppressive steroids are less aware of sick day rules Than those on endocrine replacement therapy and may be at greater risk of adrenal crisis.

Authors:  M R Salehmohamed; M Griffin; T Branigan; M Cuesta; C J Thompson
Journal:  Ir J Med Sci       Date:  2017-05-04       Impact factor: 1.568

5.  Severe hyperkalemia and bilateral adrenal metastasis.

Authors:  Michael Nagler; Beat Müller; Verena Briner; Ralph Winterhalder
Journal:  J Oncol       Date:  2010-03-02       Impact factor: 4.375

Review 6.  Adrenal cortical insufficiency--a life threatening illness with multiple etiologies.

Authors:  Marcus Quinkler; Felix Beuschlein; Stefanie Hahner; Gesine Meyer; Christof Schöfl; Günter K Stalla
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

7.  Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?

Authors:  Orhan Onder Eren; Mehmet Akif Ozturk; Basak Oyan
Journal:  Support Care Cancer       Date:  2014-01-19       Impact factor: 3.603

Review 8.  Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).

Authors:  Djillali Annane; Stephen M Pastores; Wiebke Arlt; Robert A Balk; Albertus Beishuizen; Josef Briegel; Joseph Carcillo; Mirjam Christ-Crain; Mark S Cooper; Paul E Marik; Gianfranco Umberto Meduri; Keith M Olsen; Bram Rochwerg; Sophia C Rodgers; James A Russell; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2017-09-21       Impact factor: 17.440

9.  Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.

Authors:  Tsuyoshi Miyahara; Naoko Sueoka-Aragane; Kentaro Iwanaga; Norio Ureshino; Kazutoshi Komiya; Tomomi Nakamura; Chiho Nakashima; Tomonori Abe; Hisashi Matsunaga; Shinya Kimura
Journal:  Med Oncol       Date:  2017-11-09       Impact factor: 3.064

10.  Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.

Authors:  Emilie R Elliot; Aikaterini Theodoraki; Lakshmi R Jain; Neal J Marshall; Marta Boffito; Stephanie E Baldeweg; Laura J Waters
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.